This morning Merck is scheduled to file its Q3 2026 scorecard before the opening bell, and for income investors the number that matters most is not on the income statement. It is the $0.85 quarterly dividend, $3.40 annualized, sitting against a franchise that loses U.S. market exclusivity in two years. Today is the first time the replacement strategy has to show real revenue instead of conference slides.
Analysts expected quarterly earnings of $2.12 per share, a decline of 17.8% from a year ago, on revenue of $17.23 billion. Last year’s comparable quarter came in at $2.58. The gap is not a surprise, it reflects acquisition charges tied to the Cidara deal and the Terns acquisition, but it sharpens the question every dividend investor needs to ask: can the new drugs grow fast enough to cover the payout once Keytruda biosimilars arrive?
What the 2028 Clock Actually Means
Keytruda’s U.S. compound patent expires in December 2028, with two additional patents in the composition of matter patent family expiring in May and November 2029. Merck has said it expects those two 2029 patents to be the subject of litigation and that biosimilar competition could begin in December 2028. In Q2 2026, Keytruda and Keytruda Qlex generated $8.37 billion of Merck’s $16.61 billion in worldwide sales, meaning the franchise represented roughly half of quarterly revenue. Replacing even a portion of that before biosimilar erosion begins is the central challenge in pharma today.
After U.S. exclusivity ends, biosimilar competition is expected to reduce Keytruda revenue meaningfully. Merck’s response has three parts: subcutaneous formulations, expanded indications, and acquisitions. Today’s report is where investors learn whether that three-part answer is gaining traction fast enough.
The Launch Portfolio in Focus
Three drugs carry most of the weight in the transition. Winrevair, an activin signaling inhibitor for pulmonary arterial hypertension, saw sales rise 75% in Q2 2026, largely due to continued U.S. uptake and early launch momentum in Japan and Europe. That pace needs to hold. Key focus areas for Q3 include the early trajectory of Lipfendra, an oral PCSK9 inhibitor, alongside continued adoption rates for Keytruda Qlex and other new launches.
The subcutaneous Keytruda Qlex angle matters most for the dividend thesis. Keytruda Qlex is a subcutaneously administered fixed combination of pembrolizumab and berahyaluronidase alfa, enabling under-the-skin delivery of pembrolizumab. Merck has said it expects Keytruda Qlex to reach roughly 30% to 40% penetration by 2028 through pricing and conversion from the intravenous version. If conversion accelerates in this quarter’s data, the cliff softens considerably.
The subcutaneous conversion story carries a legal complication that the penetration forecasts do not yet fully reflect. A Dutch court has already ordered Merck to stop selling Keytruda SC across eight European markets after finding patent infringement, with U.S. litigation still active.
The Dividend Math
Merck’s board declared a quarterly dividend of $0.85 per share for the third quarter of 2026. The company has raised its dividend for 16 consecutive years. The three-year dividend growth rate stands at approximately 5.5%. Those are the facts that income investors hold onto. The concern is coverage: if a company’s dividend payout ratio runs too high, the dividend may not be sustainable, and Merck’s trailing payout ratio can look elevated because GAAP earnings have been heavily distorted by acquisition-related charges. That ratio is distorted by one-time acquisition charges rather than operating weakness, but it demands scrutiny.
Merck’s full-year 2026 non-GAAP EPS guidance stands at $2.66 to $2.76. Against a $3.40 annualized dividend, the gap is visible. The honest answer is that the payout is being funded today by cash from operations, cash from operating activities was about $9.3 billion in the first six months of 2026, not by GAAP earnings clouded by deal charges. That distinction matters when assessing sustainability.
What to Watch Beyond the Headlines
The raw EPS number is almost irrelevant given the acquisition noise. Investors should focus on three signals: the Winrevair quarterly run rate and whether it is on track to cross $3 billion annually, the Keytruda Qlex conversion percentage, and any update to Lipfendra early prescription trends. The Keytruda patent cliff makes the success of Merck’s broader pipelines central to the long-term investment case. Progress on new approvals, acquisition integration, and how much revenue mix shifts away from Keytruda before December 2028 will define the outlook.
For income investors, the dividend is not in danger this year or next. The question is whether Merck’s 2027 earnings recovery, analysts’ consensus is around the high-$9 range for 2027 non-GAAP EPS, materializes on schedule. If it does, the $3.40 payout looks conservative. If launch drugs disappoint today, that recovery timeline stretches, and the yield stops looking like a floor and starts looking like a question mark.
